New druggable targets in the Ras pathway?

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 674-683

  Matallanas, David ^a   Crespo, Piero ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Antitumor therapy; B Raf; Cancer; ERK; MAPK; MEK; Ras

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; CHIR 265; EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MK 2206; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAS PROTEIN; SALIRASIB; SELUMETINIB; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 281; XL 518;

ADVANCED CANCER; APOPTOSIS; BILE DUCT CANCER; BRAIN TUMOR; BREAST CANCER; COLON CANCER; DIMERIZATION; DRUG TARGETING; ENDOMETRIUM CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; THYROID TUMOR; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 79952975186     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Malumbres M, Barbacid M: RAS oncogenes: The frst 30 years. Nat Rev Cancer (2003) 3(6):459-465.
2. Karnoub AE, Weinberg RA: RAS oncogenes: Split personalities. Nat Rev Mol Cell Biol (2008) 9(7):517-531. (Pubitemid 351881844) (Pubitemid 351881844)
3. Fehrenbacher N, Bar-Sagi D, Philips M: Ras/MAPK signaling from endomembranes. Mol Oncol (2009) 3(4):297-307.
4. Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 26(22):3291-3310. (Pubitemid 46763022) (Pubitemid 46763022)
5. COSMIC: Catalogue of somatic mutations in cancer. Wellcome Trust Sanger Institute, Cambridge, UK (2010). www.sanger.ac.uk/genetics/CGP/cosmic/
6. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, Bustelo XR: Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the Vav proto-oncogene product. Nature (1997) 385(6612):169-172. (Pubitemid 27034219) (Pubitemid 27034219)
7. Karreth FA, Tuveson DA: Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev (2009) 19(1):4-11.
8. Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL 3rd, Giguere JK, Abbruzzese JL: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study. Invest New Drugs (2005) 23(5):485-487. (Pubitemid 41160096) (Pubitemid 41160096)
9. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM et al: Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res (2001) 61(24):8758-8768. (Pubitemid 34013888) (Pubitemid 34013888)
10. Alvarado Y, Giles FJ: Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs (2007) 12(2):271-284. (Pubitemid 46953566) (Pubitemid 46953566)
11. Montagut C, Settleman J: Targeting the Raf-MEK-ERK pathway in cancer therapy. Cancer Lett (2009) 283(2):125-134.
12. Ahmadian MR, Zor T, Vogt D, Kabsch W, Selinger Z, Wittinghofer A, Scheffzek K: Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci USA (1999) 96(12): 7065-7070. (Pubitemid 29275010) (Pubitemid 29275010)
13. Fischbach MA, Settleman J: Regulation of the nucleotide state of oncogenic ras proteins by nucleoside diphosphate kinase. Methods Enzymol (2006) 407:33-45. (Pubitemid 43815936) (Pubitemid 43815936)
14. Willingham MC, Pastan I, Shih TY, Scolnick EM: Localization of the SRC gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1980) 19(4): 1005-1014. (Pubitemid 10155234) (Pubitemid 10155234)
15. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG: Post-translational modifcations and regulation of the Ras superfamily of GTPases as anticancer targets. Nat Rev Drug Discov (2007) 6(7):541-555. (Pubitemid 47019443) (Pubitemid 47019443)
16. Chen G, Oh S, Monia BP, Stacey DW: Antisense oligonucleotides demonstrate a dominant role of c-Ki-Ras proteins in regulating the proliferation of diploid human fbroblasts. J Biol Chem (1996) 271(45):28259-28265. (Pubitemid 26374638) (Pubitemid 26374638)
17. Saxena N, Lahiri SS, Hambarde S, Tripathi RP: Ras: Target for cancer therapy. Cancer Invest (2008) 26(9):948-955.
18. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y: Farnesyl derivatives of rigid carboxylic acids-inhibitors of Ras-dependent cell growth. J Med Chem (1995) 38(8): 1267-1272.
19. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R: Phase 1 frst-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol (2009) 65(2):235-241.
20. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N et al: Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-954. (Pubitemid 34716871) (Pubitemid 34716871)
21. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 62(23):6997-7000. (Pubitemid 35424092) (Pubitemid 35424092)
22. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T et al: Sorafenib for treatment of renal cell carcinoma: Final effcacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 27(20):3312-3318.
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 359(4):378-390.
24. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA et al: Clinical effcacy of a Raf inhibitor needs broad target blockade in BRaf-mutant melanoma. Nature (2010) 467(7315):596-599.
25. Wong KK: Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov (2009) 4(1):28-35.
26. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R: Gatekeeper mutations mediate resistance to BRaf-targeted therapies. Sci Transl Med (2010) 2(35):35ra41.
27. Pratilas CA, Solit DB: Targeting the mitogen-activated protein kinase pathway: Physiological feedback and drug response. Clin Cancer Res (2010) 16(13):3329-3334.
28. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: Raf inhibitors transactivate Raf dimers and ERK signalling in cells with wild-type BRaf. Nature (2010) 464(7287):427-430.
29. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T et al: Raf inhibitors prime wild-type Raf to activate the MAPK pathway and enhance growth. Nature (2010) 464(7287):431-435.
30. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R: Kinase-dead BRaf and oncogenic Ras cooperate to drive tumor progression through cRaf. Cell (2010) 140(2): 209-221.
31. Wang JY, Wilcoxen KM, Nomoto K, Wu S: Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem (2007) 7(14):1364-1378. (Pubitemid 47471235) (Pubitemid 47471235)
32. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P et al: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 23(23):5281-5293. (Pubitemid 46206982) (Pubitemid 46206982)
33. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 22(22):4456-4462. (Pubitemid 41185111) (Pubitemid 41185111)
34. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD: Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 16(6):1924-1937.
35. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L et al: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 26(13):2139-2146.
36. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM: A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16(8):2450-2457.
37. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH et al: The frst-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): A phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 16(5):1613-1623.
38. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR et al: Effective use of PI3K and MEK inhibitors to treat mutant KRas G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14(12):1351-1356.
39. Yang S, Ngo VC, Lew GB, Chong LW, Lee SS, Ong WJ, Lam WL, Thng CH, Koong HN, Ong HS, Chung A et al: AZD6244 (ARRY-142886) enhances the therapeutic effcacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther (2009) 8(9):2537-2545.
40. Frémin C, Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol (2010) 3:8.
41. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE et al: MEK1 mutations confer resistance to MEK and B-Raf inhibition. Proc Natl Acad Sci USA (2009) 106(48): 20411-20416.
42. Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt-Leopold J: A role for K-Ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia (2005) 7(4):336-347. (Pubitemid 40664223) (Pubitemid 40664223)
43. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F: PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 69(10):4286-4293.
44. Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 8(8):627-644.
45. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J et al: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 69(9): 3955-3962.
46. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M et al: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 448(7152):439-444. (Pubitemid 47123510) (Pubitemid 47123510)
47. Wong KK, Engelman JA, Cantley LC: Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2008) 20(1):87-90.
48. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene (2008) 27(41):5497-5510.
49. Carnero A: Novel inhibitors of the PI3K family. Expert Opin Investig Drugs (2009) 18(9):1265-1277.
50. Marone R, Cmiljanovic V, Giese B, Wymann MP: Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim Biophys Acta (2008) 1784(1):159-185.
51. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent effcacy in glioma. Cancer Cell (2006) 9(5):341-349. (Pubitemid 43668732) (Pubitemid 43668732)
52. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F et al: Clinical and translational studies of a phase II trial of the novel oral AKT inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res (2009) 16(3):1033-1041.
53. Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J: Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol (2009) 36(Suppl 3):S26-S36.
54. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R: FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist (2010) 15(4):428-435.
55. Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther (2007) 6(7):1909-1919. (Pubitemid 47052481) (Pubitemid 47052481)
56. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer (2010) 116(18):4256-4265.
57. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res (2006) 66(3):1500-1508. (Pubitemid 43259931) (Pubitemid 43259931)
58. Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb MH: Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell (1998) 93(4):605-615. (Pubitemid 28240721) (Pubitemid 28240721)
59. Casar B, Pinto A, Crespo P: Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell (2008) 31(5):708-721.
60. Tzivion G, Luo Z, Avruch J: A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature (1998) 394(6688):88-92. (Pubitemid 28321808) (Pubitemid 28321808)
61. Weber CK, Slupsky JR, Kalmes HA, Rapp UR: Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res (2001) 61(9):3595-3598. (Pubitemid 32694968) (Pubitemid 32694968)
62. Garnett MJ, Rana S, Paterson H, Barford D, Marais R: Wild-type and mutant B-Raf activate C-Raf through distinct mechanisms involving heterodimerization. Mol Cell (2005) 20(6):963-969. (Pubitemid 41814884) (Pubitemid 41814884)
63. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M: A dimerization-dependent mechanism drives Raf catalytic activation. Nature (2009) 461(7263):542-545.
64. Ritt DA, Monson DM, Specht SI, Morrison DK: Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol (2010) 30(3):806-819.
65. Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M: A MEK1-MEK2 heterodimer determines the strength and duration of the ERK signal. Nat Struct Mol Biol (2009) 16(3):294-303.
66. Rushworth LK, Hindley AD, O'Neill E, Kolch W: Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol (2006) 26(6):2262-2272. (Pubitemid 43346926) (Pubitemid 43346926)
67. Philips MR: Compartmentalized signalling of Ras. Biochem Soc Trans (2005) 33(Pt 4):657-661. (Pubitemid 41160832) (Pubitemid 41160832)
68. Hancock JF, Parton RG: Ras plasma membrane signalling platforms. Biochem J (2005) 389(Pt 1):1-11. (Pubitemid 40978001) (Pubitemid 40978001)
69. Calvo F, Agudo-Ibanez L, Crespo P: The Ras-ERK pathway: Understanding site-specifc signaling provides hope of new anti-tumor therapies. Bioessays (2010) 32(5):412-421.
70. Matallanas D, Sanz-Moreno V, Arozarena I, Calvo F, Agudo-Ibanez L, Santos E, Berciano MT, Crespo P: Distinct utilization of effectors and biological outcomes resulting from site-specifc Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation. Mol Cell Biol (2006) 26(1):100-116.
71. Grewal T, Enrich C: Molecular mechanisms involved in Ras inactivation: The annexin A6-p120GAP complex. Bioessays (2006) 28(12):1211-1220. (Pubitemid 44925441) (Pubitemid 44925441)
72. Rotblat B, Niv H, Andre S, Kaltner H, Gabius HJ, Kloog Y: Galectin-1(L11A) predicted from a computed Galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res (2004) 64(9):3112-3118. (Pubitemid 38581411) (Pubitemid 38581411)
73. Robinson MJ, Cobb MH: Mitogen-activated protein kinases pathways. Curr Opin Cell Biol (1997) 9 180-186.
74. Yoon S, Seger R: The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors (2006) 24(1):21-44. (Pubitemid 43108774) (Pubitemid 43108774)
75. Glading A, Koziol JA, Krueger J, Ginsberg MH: PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res (2007) 67(4):1536-1544. (Pubitemid 46383377) (Pubitemid 46383377)
76. Mebratu YA, Dickey BF, Evans C, Tesfaigzi Y: The BH3-only protein Bik/Blk/Nbk inhibits nuclear translocation of activated ERK1/2 to mediate IFN-induced cell death. J Cell Biol (2008) 183(3):429-439.
77. Chen CH, Wang WJ, Kuo JC, Tsai HC, Lin JR, Chang ZF, Chen RH: Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. Embo J (2005) 24(2):294-304.
78. Chuderland D, Konson A, Seger R: Identifcation and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell (2008) 31(6):850-861.
79. Dhanasekaran DN, Kashef K, Lee CM, Xu H, Reddy EP: Scaffold proteins of MAP-kinase modules. Oncogene (2007) 26(22):3185-3202. (Pubitemid 46763014) (Pubitemid 46763014)
80. Casar B, Arozarena I, Sanz-Moreno V, Pinto A, Agudo-Ibanez L, Marais R, Lewis RE, Berciano MT, Crespo P: Ras subcellular localization defnes extracellular signal-regulated kinase 1 and 2 substrate specifcity through distinct utilization of scaffold proteins. Mol Cell Biol (2009) 29(5):1338-1353.
81. Matheny SA, Chen C, Kortum RL, Razidlo GL, Lewis RE, White MA: Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature (2004) 427(6971): 256-260. (Pubitemid 38112042) (Pubitemid 38112042)
82. Teis D, Wunderlich W, Huber LA: Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell (2002) 3(6):803-814. (Pubitemid 35460781) (Pubitemid 35460781)
83. Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E: Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell (2004) 7(1):33-44. (Pubitemid 39172686) (Pubitemid 39172686)
84. Ishibe S, Joly D, Zhu X, Cantley LG: Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell (2003) 12(5):1275-1285. (Pubitemid 37487934) (Pubitemid 37487934)
85. Shenoy SK, Lefkowitz RJ: Receptor-specifc ubiquitination of β-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J Biol Chem (2005) 280(15):15315-15324. (Pubitemid 40562888) (Pubitemid 40562888)
86. Nguyen A, Burack WR, Stock JL, Kortum R, Chaika OV, Afkarian M, Muller WJ, Murphy KM, Morrison DK, Lewis RE, McNeish J et al: Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol (2002) 22(9):3035-3045. (Pubitemid 34437462) (Pubitemid 34437462)
87. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F: Opposing effects of Ras on p53: Transcriptional activation of MDM2 and induction of p19ARF. Cell (2000) 103(2):321-330.
88. Feig LA, Buchsbaum RJ: Cell signaling: Life or death decisions of Ras proteins. Curr Biol (2002) 12(7):R259-R261. (Pubitemid 34271362) (Pubitemid 34271362)
89. Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J: Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J (2004) 381(Pt 2):453-462. (Pubitemid 38969690) (Pubitemid 38969690)
90. Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, Kolch W, Latif F: RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene (2009) 28(33):2988-2998.
91. Matallanas D, Romano D, Hamilton G, Kolch W, O'Neill E: A hippo in the ointment: MST signalling beyond the fy. Cell Cycle (2008) 7(7):879-884. (Pubitemid 351573781) (Pubitemid 351573781)
92. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, Baccarini M, Vass JK, Kolch W, O'Neill E: RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 27(6):962-975. (Pubitemid 47495894) (Pubitemid 47495894)
93. Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T, Kolch W: Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and AKT. Cancer Res (2010) 70(3):1195-1203.
94. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell (2009) 136(5): 823-837.
95. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ: A genome-wide RNAi screen identifes multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 137(5):835-848.
96. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Dohner K et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 137(5):821-834.
97. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 462(7269): 108-112.
98. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRaf in metastatic melanoma. N Engl J Med 363(9):809-819.
99. Mita MM, Tolcher AW: The role of mTOR inhibitors for treatment of sarcomas. Curr Oncol Rep (2007) 9(4):316-322. (Pubitemid 47045166) (Pubitemid 47045166)
100. Dancey JE, Curiel R, Purvis J: Evaluating temsirolimus activity in multiple tumors: A review of clinical trials. Semin Oncol (2009) 36(Suppl 3):S46-S58.